Heron Therapeutics (HRTX) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 18, 2019
Document Information [Line Items]
Entity Registrant Name	HERON THERAPEUTICS, INC. /DE/
Entity Central Index Key	0000818033
Trading Symbol	hrtx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		79,069,527
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 23,461	$ 31,836
Short-term investments	265,777	300,535
Accounts receivable, net	74,007	64,652
Inventory	31,421	39,032
Prepaid expenses and other current assets	11,539	11,193
Total current assets	406,205	447,248
Property and equipment, net	16,267	14,677
Right-of-use lease assets	13,068
Other assets	254	254
Total assets	435,794	462,179
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	10,811	16,863
Accrued clinical and manufacturing liabilities	23,602	24,470
Accrued payroll and employee liabilities	6,640	13,397
Other accrued liabilities	44,351	32,715
Current lease liabilities	2,032
Convertible notes payable to related parties, net of discount	4,821	4,574
Total current liabilities	92,257	92,019
Non-current lease liabilities	11,723
Total liabilities	103,980	92,019
Stockholders’ equity:
Common stock	789	782
Additional paid-in capital	1,354,722	1,330,186
Accumulated other comprehensive income (loss)	36	(87)
Accumulated deficit	(1,023,733)	(960,721)
Total stockholders’ equity	331,814	370,160
Total liabilities and stockholders’ equity	$ 435,794	$ 462,179

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Net product sales	$ 31,602	$ 11,567
Operating expenses:
Cost of product sales	14,962	3,133
Research and development	42,972	39,561
General and administrative	9,648	7,028
Sales and marketing	28,720	13,835
Total operating expenses	96,302	63,557
Loss from operations	(64,700)	(51,990)
Other income (expense), net	1,688	(275)
Net loss	(63,012)	(52,265)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	123	(32)
Comprehensive loss	$ (62,889)	$ (52,297)
Basic and diluted net loss per share (in dollars per share)	$ (0.80)	$ (0.81)
Shares used in computing basic and diluted net loss per share (in shares)	78,419	64,724

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	64,609
Balance at Dec. 31, 2017	$ 646	$ 913,955	$ (10)	$ (783,455)	$ 131,136
Conversion benefit included in Convertible Notes issued		96			96
Issuance of common stock on exercise of stock options (in shares)	485
Issuance of common stock on exercise of stock options	$ 4	4,198			4,202
Stock-based compensation expense		7,701			7,701
Net loss				(52,265)	(52,265)
Unrealized gain (loss) on short-term investments			(32)		(32)
Comprehensive loss					(52,297)
Cumulative effect of adoption of new accounting standard at Dec. 31, 2017				1,573	1,573
Issuance of common stock in public offerings, net		(205)			(205)
Balance (in shares) at Mar. 31, 2018	65,094
Balance at Mar. 31, 2018	$ 650	925,745	(42)	(834,147)	92,206
Balance (in shares) at Dec. 31, 2018	78,174
Balance at Dec. 31, 2018	$ 782	1,330,186	(87)	(960,721)	370,160
Conversion benefit included in Convertible Notes issued		102			$ 102
Issuance of common stock on exercise of stock options (in shares)	732				732
Issuance of common stock on exercise of stock options	$ 7	6,532			$ 6,539
Stock-based compensation expense		17,902			17,902
Net loss				(63,012)	(63,012)
Unrealized gain (loss) on short-term investments			123		123
Comprehensive loss					(62,889)
Balance (in shares) at Mar. 31, 2019	78,906
Balance at Mar. 31, 2019	$ 789	$ 1,354,722	$ 36	$ (1,023,733)	$ 331,814

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities:
Net loss	$ (63,012,000)	$ (52,265,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Stock-based compensation expense	17,902,000	7,701,000
Depreciation and amortization	467,000	381,000
Amortization of debt discount	247,000	210,000
Realized gain on short-term investments	(8,000)	0
Accretion of discount on short-term investments	(1,357,000)	(211,000)
Impairment on property and equipment	27,000
Loss on disposal of property and equipment	52,000
Change in operating assets and liabilities:
Accounts receivable	(9,355,000)	4,161,000
Prepaid expenses and other assets	(346,000)	(1,845,000)
Inventory	7,611,000	(9,508,000)
Accounts payable	(6,052,000)	(7,311,000)
Accrued clinical and manufacturing liabilities	(868,000)	(1,986,000)
Accrued payroll and employee liabilities	(6,757,000)	(3,612,000)
Other accrued liabilities	12,425,000	2,572,000
Net cash used for operating activities	(49,024,000)	(61,713,000)
Investing activities:
Purchases of short-term investments	(127,763,000)	(39,388,000)
Maturities and sales of short-term investments	164,009,000
Purchases of property and equipment	(2,136,000)	(904,000)
Net cash provided by (used for) investing activities	34,110,000	(40,292,000)
Financing activities:
Net proceeds from sale of common stock		(205,000)
Proceeds from stock option exercises	6,539,000	4,202,000
Net cash provided by financing activities	6,539,000	3,997,000
Net decrease in cash and cash equivalents	(8,375,000)	(98,008,000)
Cash and cash equivalents at beginning of year	31,836,000	144,583,000
Cash and cash equivalents at end of period	23,461,000	46,575,000
Supplemental disclosure of cash flow information:
Interest paid		500,000
Cumulative effect of adoption of new accounting standard		$ 1,573,000

Note 1 - Business

Note 1 - Business	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. We are a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, first 5 3 ≥5 October 2016. On November 9, 2017, second 1 “NK1” NK1 80 January 2018. February 26, 2019, 30 2 HTX- 011, 011 011 five 011 fourth 2017 second 2018. 011 October 2018 December 2018. 011 April 30, 2019. not no April 2019, 011 011 first 2020. HTX- 034, 034 seven As of March 31, 2019 $289.2 March 31, 2019 one 10

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2 . Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10 10 X. not three March 31, 2019 not may December 31, 2019. December 31, 2018 not 10 December 31, 2018, February 22, 2019.

Note 3 - Accounting Policies

Note 3 - Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly-owned subsidiary, Heron Therapeutics, B.V., which was organized in the Netherlands in March 2015. no no no Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, inventory and the related reserves, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates. Ca sh, Cash Equivalents and Short-t erm Investments Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of three Short-term investments consist of securities with contractual maturities of greater than three one Our bank and investment accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) (see Note 8 Concentration of Credit Risk Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may may Our products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell our products to healthcare providers and hospitals, the end users. The following table includes the percentage of net product sales and accounts receivable balances for our three 10% Net Product Sales Accounts Receivable Three Months March 31, 2019 As of March 31, 2019 Customer A 40.7 % 42.3 % Customer B 36.6 % 39.2 % Customer C 20.4 % 17.5 % Total 97.7 % 99.0 % Accounts Receivable, Net Accounts receivable are recorded at the invoice amount, net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for doubtful accounts, we consider: ( 1 2 3 We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in October 2016 January 2018, January 2018, March 31, 2019, not As of March 31, 2019, not three March 31, 2019, not Inventory Inventory is stated at the lower of cost or estimated net realizable value on a first first may Leases In February 2016, No. 2016 02, Leases (Topic 842 2016 02” July 2018, No. 2018 11, Leases (Topic 842 No. 2018 10, Codification Improvements to Topic 842, 2016 02 842.” 842 not twelve twelve 842 December 15, 2018, We adopted ASC 842 January 1, 2019 No. 2018 11. not 12 842 no 7 We determine if an agreement is a lease or contains lease components at inception. Operating leases are recorded as lease liabilities with corresponding ROU lease assets on the condensed consolidated balance sheets. ROU lease assets represent our right to use the underlying assets over the lease term, and lease liabilities represent the present value of our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement based on the present value of lease payments over the lease term. As most of our leases do not Revenue Recognition In May 2014, No. 2014 09, Revenue from Contracts with Customers 606” 606 first 2018, 606 2018 606, $1.6 January 1, 2018. $2.9 $1.1 $0.2 Product Sales SUSTOL is distributed in the U.S. through a limited number of Customers that resell SUSTOL to healthcare providers, the end users of SUSTOL. CINVANTI is distributed in the U.S. through a limited number of Customers that resell CINVANTI to healthcare providers and hospitals, the end users of CINVANTI. Revenue is recognized in an amount that reflects the consideration we expect to receive in exchange for our products. To determine revenue recognition for contracts with customers within the scope of Topic 606, five Product Sales Allowances We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with Customers, historical product returns, rebates or discounts taken, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. If actual future results vary from our estimates, we may ● Product Returns — We allow our Customers to return product for credit 12 may ● Distributor Fees — We offer contractually determined discounts to our Customers. These discounts are paid no two ● Group Purchasing Organization (“GPO”) Discounts and Rebates — We offer cash discounts to GPO members. These discounts are taken when the GPO members purchase SUSTOL or CINVANTI from our Customers, who then charge back to us the discount amount. Additionally, we offer volume and contract-tier rebates to GPO members. Rebates are based on actual purchase levels during the quarterly rebate purchase period. ● GPO Administrative Fees — We pay administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs’ members. ● Medicaid Rebates — We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three We believe our estimated allowance for product returns requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. We believe our estimated allowances for distributor fees, GPO discounts, rebates and administrative fees and Medicaid rebates do not Our product sales allowances and related accruals are evaluated each reporting period and adjusted when trends or significant events indicate that a change in estimate is appropriate. Changes in sales allowance estimates could materially affect our results of operations and financial position. The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands): Product Returns Distributor Fees Discounts, Rebates and Administrative Fees Total Balance at December 31, 2018 $ 947 $ 2,813 $ 21,743 $ 25,503 Provision 332 3,825 30,642 34,799 Payments/credits (3 ) (3,289 ) (22,945 ) (26,237 ) Balance at March 31, 2019 $ 1,276 $ 3,349 $ 29,440 $ 34,065 Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive loss. Net L oss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and shares of common stock underlying Convertible Notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive. Because we have incurred a net loss for each of the periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not March 31 , 2019 2018 Stock options outstanding 14,281 12,906 Warrants outstanding 640 640 Shares of common stock underlying Convertible Notes outstanding 8,600 8,103 Recent Accounting Pronouncements In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 2018 13” 2018 13 December 15, 2019, 2018 13 first 2020, In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 2016 13” 2016 13 December 15, 2019, 2016 13 first 2020,

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The FASB Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures ● Level 1 ● Level 2 1 not ● Level 3 no We measure cash, cash equivalents and short-term investments at fair value on a recurring basis. The fair values of such assets were as follows (in thousands): Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Active Markets Other Significant Balance at for Identical Observable Unobservable March 31, Assets Inputs Inputs 201 9 (Level 1) (Level 2) (Level 3) Cash and money market funds $ 23,461 $ 23,461 $ — $ — U.S. treasury bills and government agency obligations 89,283 89,283 — — U.S. corporate debt securities 51,310 — 51,310 — Foreign corporate debt securities 5,038 — 5,038 — U.S. commercial paper 50,176 — 50,176 — Foreign commercial paper 69,970 — 69,970 — Total $ 289,238 $ 112,744 $ 176,494 $ — Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Active Markets Other Significant Balance at for Identical Observable Unobservable December 31, Assets Inputs Inputs 201 8 (Level 1) (Level 2) (Level 3) Cash and money market funds $ 22,751 $ 22,751 $ — $ — U.S. treasury bills and government agency obligations 59,741 59,741 — — U.S. corporate debt securities 59,087 — 59,087 — Foreign corporate debt securities 5,046 — 5,046 — U.S. commercial paper 61,885 — 61,885 — Foreign commercial paper 123,861 — 123,861 — Total $ 332,371 $ 82,492 $ 249,879 $ — We have not three As of March 31, 2019, $265.8 three one December 31, 2018, $9.1 three $300.5 three one March 31, 2019 December 31, 2018 A company may not third not not Financial instruments, including cash, cash equivalents, receivables, inventory, prepaid expenses, other current assets, accounts payable and accrued expenses are carried at cost, which is considered to be representative of their respective fair values because of the short-term maturity of these instruments. Short-term available-for-sale investments are carried at fair value. Our Convertible Notes outstanding at March 31, 2019 not

Note 5 - Short-term Investments

Note 5 - Short-term Investments	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	5. The following is a summary of our short-term investments (in thousands): March 31, 2019 Gross Gross Amortized Unrealized Unrealized Estimated Cost Gains Losses Fair Value U.S. treasury bills and government agency obligations $ 89,255 $ 28 $ — $ 89,283 U.S. corporate debt securities 51,311 — (1 ) 51,310 Foreign corporate debt securities 5,027 11 — 5,038 U.S. commercial paper 50,176 — — 50,176 Foreign commercial paper 69,972 — (2 ) 69,970 Total $ 265,741 $ 39 $ (3 ) $ 265,777 December 31, 2018 Gross Gross Amortized Unrealized Unrealized Estimated Cost Gains Losses Fair Value U.S. treasury bills and government agency obligations $ 59,747 $ — $ (6 ) $ 59,741 U.S. corporate debt securities 59,164 — (77 ) 59,087 Foreign corporate debt securities 5,041 5 — 5,046 U.S. commercial paper 52,800 — — 52,800 Foreign commercial paper 123,870 — (9 ) 123,861 Total $ 300,622 $ 5 $ (92 ) $ 300,535 The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. We regularly monitor and evaluate the realizable value of our marketable securities. We did not three March 31, 2019 2018. Realized gains and losses associated with our investments, if any, are reported in the statements of operations and comprehensive loss. We recognized $8,000 three March 31, 2019. not three March 31, 2018.

Note 6 - Inventory

Note 6 - Inventory	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventory consists of the following (in thousands): March 31, 2019 Decemb er 31, 2018 Raw materials $ 9,379 $ 10,112 Work in process 14,770 20,604 Finished goods 7,272 8,316 Total inventory $ 31,421 $ 39,032 As of March 31, 2019, $4.2 $27.2 December 31, 2018, $6.7 $32.3

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. As of March 31, 2019, 81 two three On January 1, 2019, 842, $13.7 $14.5 81 not three March 31, 2019, $0.9 three March 31, 2019, $1.0 Future minimum lease payments under our operating leases are as follows (in thousands): Year Ending March 31, 2020 $ 2,941 2021 2,742 2022 2,821 2023 2,904 2024 2,988 Thereafter 2,514 Total future minimum lease payments $ 16,910 Less: discount (3,155 ) Total lease liabilities $ 13,755

Note 8 - Secured Notes to Relat

Note 8 - Secured Notes to Related Party	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Convertible Notes In April 2011, $4.5 no $4.3 The Convertible Notes are secured by substantially all of our assets, including placing our bank and investment accounts under a control agreement. The Convertible Notes bear interest at 6% May 2, 2021; may The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 $1,000 no 9.99% not 61 As of March 31, 2019, In 2011, 3.5 July 29, 2011. The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 $1,000 10 three March 31, 2019, $0.1 $0.1 three March 31, 2019, 2018, $0.1 three March 31, 2019 2018, $0.2 As of March 31, 2019, $4.8 $6.9 $2.1 March 31, 2019, 8.6 Promissory Note In August 2016, $100.0 two 8% first $50.0 August 5, 2016. second $50.0 not no no no second no For the three March 31, 2018, $0.5 August 2018, $25.0 $0.2 March 31, 2019, no

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Common Stock Offering s In April 2018, 6.9 $26.00 $168.7 $10.7 In June 2018, 5.1 $39.50 $194.4 $5.6 Stock Option Activity The following table summarizes the stock option activity for the three March 31, 2019: Weighted- a verage Weighted- Remaining a verage Contractual Shares Exercise Term (in thousands) Price (Years) Balance at December 31, 2018 15,265 $ 18.33 6.87 Granted 253 $ 25.99 Exercised (732 ) $ 8.93 Expired and forfeited (505 ) $ 21.11 Balance at March 31, 2019 14,281 $ 18.85 7.19 For the three March 31, 2019, 732,000 $6.5 Stock-based Compensation The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements (in thousands): Three Months Ended March 31, 2019 2018 Research and development $ 5,324 $ 3,036 General and administrative 3,680 2,276 Sales and marketing 8,898 2,389 Total stock-based compensation expense $ 17,902 $ 7,701 As of March 31, 2019, $100.3 2.6 We estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: March 31, 20 19 20 18 Risk-free interest rate 2.5 % 2.6 % Dividend yield 0.0 % 0.0 % Volatility 68.8 % 71.4 % Expected life (years) 6 6 We estimated the fair value of each purchase right granted under our 1997 no three March 31, 2019 2018.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10 . Income Taxes Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. We continue to maintain a full valuation allowance against our deferred tax assets as of March 31, 2019. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not not 10 December 31, 2018, February 22, 2019, three March 31, 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly-owned subsidiary, Heron Therapeutics, B.V., which was organized in the Netherlands in March 2015. no no no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, inventory and the related reserves, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.
Cash, Cash Equivalents, and Short-Term Investments [Policy Text Block]	Ca sh, Cash Equivalents and Short-t erm Investments Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of three Short-term investments consist of securities with contractual maturities of greater than three one Our bank and investment accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) (see Note 8
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may may Our products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell our products to healthcare providers and hospitals, the end users. The following table includes the percentage of net product sales and accounts receivable balances for our three 10% Net Product Sales Accounts Receivable Three Months March 31, 2019 As of March 31, 2019 Customer A 40.7 % 42.3 % Customer B 36.6 % 39.2 % Customer C 20.4 % 17.5 % Total 97.7 % 99.0 %
Receivable [Policy Text Block]	Accounts Receivable, Net Accounts receivable are recorded at the invoice amount, net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for doubtful accounts, we consider: ( 1 2 3 We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in October 2016 January 2018, January 2018, March 31, 2019, not As of March 31, 2019, not three March 31, 2019, not
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or estimated net realizable value on a first first may
Lessee, Leases [Policy Text Block]	Leases In February 2016, No. 2016 02, Leases (Topic 842 2016 02” July 2018, No. 2018 11, Leases (Topic 842 No. 2018 10, Codification Improvements to Topic 842, 2016 02 842.” 842 not twelve twelve 842 December 15, 2018, We adopted ASC 842 January 1, 2019 No. 2018 11. not 12 842 no 7 We determine if an agreement is a lease or contains lease components at inception. Operating leases are recorded as lease liabilities with corresponding ROU lease assets on the condensed consolidated balance sheets. ROU lease assets represent our right to use the underlying assets over the lease term, and lease liabilities represent the present value of our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement based on the present value of lease payments over the lease term. As most of our leases do not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition In May 2014, No. 2014 09, Revenue from Contracts with Customers 606” 606 first 2018, 606 2018 606, $1.6 January 1, 2018. $2.9 $1.1 $0.2 Product Sales SUSTOL is distributed in the U.S. through a limited number of Customers that resell SUSTOL to healthcare providers, the end users of SUSTOL. CINVANTI is distributed in the U.S. through a limited number of Customers that resell CINVANTI to healthcare providers and hospitals, the end users of CINVANTI. Revenue is recognized in an amount that reflects the consideration we expect to receive in exchange for our products. To determine revenue recognition for contracts with customers within the scope of Topic 606, five Product Sales Allowances We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with Customers, historical product returns, rebates or discounts taken, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. If actual future results vary from our estimates, we may ● Product Returns — We allow our Customers to return product for credit 12 may ● Distributor Fees — We offer contractually determined discounts to our Customers. These discounts are paid no two ● Group Purchasing Organization (“GPO”) Discounts and Rebates — We offer cash discounts to GPO members. These discounts are taken when the GPO members purchase SUSTOL or CINVANTI from our Customers, who then charge back to us the discount amount. Additionally, we offer volume and contract-tier rebates to GPO members. Rebates are based on actual purchase levels during the quarterly rebate purchase period. ● GPO Administrative Fees — We pay administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs’ members. ● Medicaid Rebates — We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three We believe our estimated allowance for product returns requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. We believe our estimated allowances for distributor fees, GPO discounts, rebates and administrative fees and Medicaid rebates do not Our product sales allowances and related accruals are evaluated each reporting period and adjusted when trends or significant events indicate that a change in estimate is appropriate. Changes in sales allowance estimates could materially affect our results of operations and financial position. The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands): Product Returns Distributor Fees Discounts, Rebates and Administrative Fees Total Balance at December 31, 2018 $ 947 $ 2,813 $ 21,743 $ 25,503 Provision 332 3,825 30,642 34,799 Payments/credits (3 ) (3,289 ) (22,945 ) (26,237 ) Balance at March 31, 2019 $ 1,276 $ 3,349 $ 29,440 $ 34,065
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive loss.
Earnings Per Share, Policy [Policy Text Block]	Net L oss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and shares of common stock underlying Convertible Notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive. Because we have incurred a net loss for each of the periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not March 31 , 2019 2018 Stock options outstanding 14,281 12,906 Warrants outstanding 640 640 Shares of common stock underlying Convertible Notes outstanding 8,600 8,103
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 2018 13” 2018 13 December 15, 2019, 2018 13 first 2020, In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 2016 13” 2016 13 December 15, 2019, 2016 13 first 2020,

Note 3 - Accounting Policies (T

Note 3 - Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Net Product Sales Accounts Receivable Three Months March 31, 2019 As of March 31, 2019 Customer A 40.7 % 42.3 % Customer B 36.6 % 39.2 % Customer C 20.4 % 17.5 % Total 97.7 % 99.0 %
Valuation Allowances and Reserves [Table Text Block]	Product Returns Distributor Fees Discounts, Rebates and Administrative Fees Total Balance at December 31, 2018 $ 947 $ 2,813 $ 21,743 $ 25,503 Provision 332 3,825 30,642 34,799 Payments/credits (3 ) (3,289 ) (22,945 ) (26,237 ) Balance at March 31, 2019 $ 1,276 $ 3,349 $ 29,440 $ 34,065
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31 , 2019 2018 Stock options outstanding 14,281 12,906 Warrants outstanding 640 640 Shares of common stock underlying Convertible Notes outstanding 8,600 8,103

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Active Markets Other Significant Balance at for Identical Observable Unobservable March 31, Assets Inputs Inputs 201 9 (Level 1) (Level 2) (Level 3) Cash and money market funds $ 23,461 $ 23,461 $ — $ — U.S. treasury bills and government agency obligations 89,283 89,283 — — U.S. corporate debt securities 51,310 — 51,310 — Foreign corporate debt securities 5,038 — 5,038 — U.S. commercial paper 50,176 — 50,176 — Foreign commercial paper 69,970 — 69,970 — Total $ 289,238 $ 112,744 $ 176,494 $ — Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Active Markets Other Significant Balance at for Identical Observable Unobservable December 31, Assets Inputs Inputs 201 8 (Level 1) (Level 2) (Level 3) Cash and money market funds $ 22,751 $ 22,751 $ — $ — U.S. treasury bills and government agency obligations 59,741 59,741 — — U.S. corporate debt securities 59,087 — 59,087 — Foreign corporate debt securities 5,046 — 5,046 — U.S. commercial paper 61,885 — 61,885 — Foreign commercial paper 123,861 — 123,861 — Total $ 332,371 $ 82,492 $ 249,879 $ —

Note 5 - Short-term Investmen_2

Note 5 - Short-term Investments (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Debt Securities, Available-for-sale [Table Text Block]	March 31, 2019 Gross Gross Amortized Unrealized Unrealized Estimated Cost Gains Losses Fair Value U.S. treasury bills and government agency obligations $ 89,255 $ 28 $ — $ 89,283 U.S. corporate debt securities 51,311 — (1 ) 51,310 Foreign corporate debt securities 5,027 11 — 5,038 U.S. commercial paper 50,176 — — 50,176 Foreign commercial paper 69,972 — (2 ) 69,970 Total $ 265,741 $ 39 $ (3 ) $ 265,777 December 31, 2018 Gross Gross Amortized Unrealized Unrealized Estimated Cost Gains Losses Fair Value U.S. treasury bills and government agency obligations $ 59,747 $ — $ (6 ) $ 59,741 U.S. corporate debt securities 59,164 — (77 ) 59,087 Foreign corporate debt securities 5,041 5 — 5,046 U.S. commercial paper 52,800 — — 52,800 Foreign commercial paper 123,870 — (9 ) 123,861 Total $ 300,622 $ 5 $ (92 ) $ 300,535

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2019 Decemb er 31, 2018 Raw materials $ 9,379 $ 10,112 Work in process 14,770 20,604 Finished goods 7,272 8,316 Total inventory $ 31,421 $ 39,032

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending March 31, 2020 $ 2,941 2021 2,742 2022 2,821 2023 2,904 2024 2,988 Thereafter 2,514 Total future minimum lease payments $ 16,910 Less: discount (3,155 ) Total lease liabilities $ 13,755

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted- a verage Weighted- Remaining a verage Contractual Shares Exercise Term (in thousands) Price (Years) Balance at December 31, 2018 15,265 $ 18.33 6.87 Granted 253 $ 25.99 Exercised (732 ) $ 8.93 Expired and forfeited (505 ) $ 21.11 Balance at March 31, 2019 14,281 $ 18.85 7.19
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2019 2018 Research and development $ 5,324 $ 3,036 General and administrative 3,680 2,276 Sales and marketing 8,898 2,389 Total stock-based compensation expense $ 17,902 $ 7,701
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 31, 20 19 20 18 Risk-free interest rate 2.5 % 2.6 % Dividend yield 0.0 % 0.0 % Volatility 68.8 % 71.4 % Expected life (years) 6 6

Note 1 - Business (Details Text

Note 1 - Business (Details Textual) $ in Millions	Mar. 31, 2019USD ($)
Cash, Cash Equivalents, and Short-term Investments, Total	$ 289.2

Note 3 - Accounting Policies (D

Note 3 - Accounting Policies (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Cumulative Effect of New Accounting Principle in Period of Adoption					$ 1,573
Revenue from Contract with Customer, Including Assessed Tax		$ 31,602	$ 11,567
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance		34,065		$ 25,503
Cost of Goods and Services Sold, Total		$ 14,962	$ 3,133
Accounting Standards Update 2014-09 [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 2,900
Cost of Goods and Services Sold, Total	200
Accounting Standards Update 2014-09 [Member] | Product Sales Allowance [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	1,100
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					$ 1,573
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 1,600

Note 3 - Accounting Policies -

Note 3 - Accounting Policies - Percentage of Net Product Sales and Accounts Receivable Balance (Details) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2019
Revenue Benchmark [Member]
Concentration risk percentage	97.70%
Revenue Benchmark [Member] | Largest Customer [Member]
Concentration risk percentage	40.70%
Revenue Benchmark [Member] | Second Largest Customer [Member]
Concentration risk percentage	36.60%
Revenue Benchmark [Member] | Third Largest Customer [Member]
Concentration risk percentage	20.40%
Accounts Receivable [Member]
Concentration risk percentage	99.00%
Accounts Receivable [Member] | Largest Customer [Member]
Concentration risk percentage	42.30%
Accounts Receivable [Member] | Second Largest Customer [Member]
Concentration risk percentage	39.20%
Accounts Receivable [Member] | Third Largest Customer [Member]
Concentration risk percentage	17.50%

Note 3 - Accounting Policies _2

Note 3 - Accounting Policies - Summary of Product Sales Allowance (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Balance	$ 25,503
Provision	34,799
Payments/credits	(26,237)
Balance	34,065
Allowance for Sales Returns 1 [Member]
Balance	947
Provision	332
Payments/credits	(3)
Balance	1,276
Allowance for Distributor Fees [Member]
Balance	2,813
Provision	3,825
Payments/credits	(3,289)
Balance	3,349
Allowance for Rebates and Chargebacks [Member]
Balance	21,743
Provision	30,642
Payments/credits	(22,945)
Balance	$ 29,440

Note 3 - Accounting Policies _3

Note 3 - Accounting Policies - Securities Excluded From Calculation of Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Option [Member]
Shares excluded (in shares)	14,281	12,906
Warrant [Member]
Shares excluded (in shares)	640	640
Convertible Debt Securities [Member]
Shares excluded (in shares)	8,600	8,103

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Cash Equivalents, at Carrying Value, Total	$ 265,800	$ 9,100
Available-for-sale Securities, Current, Total	$ 265,777	$ 300,535

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Available-for-sale securities	$ 265,777	$ 300,535
US Treasury Securities [Member]
Available-for-sale securities	89,283	59,741
Debt Security, Corporate, US [Member]
Available-for-sale securities	51,310	59,087
Debt Security, Corporate, Non-US [Member]
Available-for-sale securities	5,038	5,046
United States Commercial Paper [Member]
Available-for-sale securities	50,176	52,800
Foreign Commercial Paper [Member]
Available-for-sale securities	69,970	123,861
Fair Value, Recurring [Member]
Total	289,238	332,371
Fair Value, Recurring [Member] | Foreign Commercial Paper [Member]
Available-for-sale securities	69,970	123,861
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Available-for-sale securities	89,283	59,741
Fair Value, Recurring [Member] | Debt Security, Corporate, US [Member]
Available-for-sale securities	51,310	59,087
Fair Value, Recurring [Member] | Debt Security, Corporate, Non-US [Member]
Available-for-sale securities	5,038	5,046
Fair Value, Recurring [Member] | United States Commercial Paper [Member]
Available-for-sale securities	50,176	61,885
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total	112,744	82,492
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Available-for-sale securities	89,283	59,741
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Debt Security, Corporate, US [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Debt Security, Corporate, Non-US [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | United States Commercial Paper [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Commercial Paper [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total	176,494	249,879
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Debt Security, Corporate, US [Member]
Available-for-sale securities	51,310	59,087
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Debt Security, Corporate, Non-US [Member]
Available-for-sale securities	5,038	5,046
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | United States Commercial Paper [Member]
Available-for-sale securities	50,176	61,885
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Commercial Paper [Member]
Available-for-sale securities	69,970	123,861
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Debt Security, Corporate, US [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Debt Security, Corporate, Non-US [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | United States Commercial Paper [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Commercial Paper [Member]
Available-for-sale securities
Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash and money market funds	23,461	22,751
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and money market funds	23,461	22,751
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and money market funds
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and money market funds

Note 5 - Short-term Investmen_3

Note 5 - Short-term Investments (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total	$ 0	$ 0
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	$ 8,000	$ 0

Note 5 - Short-term Investmen_4

Note 5 - Short-term Investments - Summary of Short-term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Available-for-sale securities, amortized cost	$ 265,741	$ 300,622
Available-for-sale securities, gross unrealized gains	39	5
Available-for-sale securities, gross unrealized losses	(3)	(92)
Available-for-sale securities	265,777	300,535
US Treasury Securities [Member]
Available-for-sale securities, amortized cost	89,255	59,747
Available-for-sale securities, gross unrealized gains	28
Available-for-sale securities, gross unrealized losses		(6)
Available-for-sale securities	89,283	59,741
Debt Security, Corporate, US [Member]
Available-for-sale securities, amortized cost	51,311	59,164
Available-for-sale securities, gross unrealized gains
Available-for-sale securities, gross unrealized losses	(1)	(77)
Available-for-sale securities	51,310	59,087
Debt Security, Corporate, Non-US [Member]
Available-for-sale securities, amortized cost	5,027	5,041
Available-for-sale securities, gross unrealized gains	11	5
Available-for-sale securities, gross unrealized losses
Available-for-sale securities	5,038	5,046
United States Commercial Paper [Member]
Available-for-sale securities, amortized cost	50,176	52,800
Available-for-sale securities, gross unrealized gains
Available-for-sale securities, gross unrealized losses
Available-for-sale securities	50,176	52,800
Foreign Commercial Paper [Member]
Available-for-sale securities, amortized cost	69,972	123,870
Available-for-sale securities, gross unrealized gains
Available-for-sale securities, gross unrealized losses	(2)	(9)
Available-for-sale securities	$ 69,970	$ 123,861

Note 6 - Inventory (Details Tex

Note 6 - Inventory (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory, Net, Total	$ 31,421	$ 39,032
SUSTOL [Member]
Inventory, Net, Total	4,200	6,700
CINVANTI [Member]
Inventory, Net, Total	$ 27,200	$ 32,300

Note 6 - Inventory - Inventory

Note 6 - Inventory - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Raw materials	$ 9,379	$ 10,112
Work in process	14,770	20,604
Finished goods	7,272	8,316
Total inventory	$ 31,421	$ 39,032

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 13,068
Operating Lease, Liability, Total	$ 13,755
Operating Lease, Weighted Average Remaining Lease Term	6 years 270 days
Operating Lease, Expense	$ 900
Operating Lease, Payments	$ 1,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		$ 13,700
Operating Lease, Liability, Total		$ 14,500
Minimum [Member]
Lessee, Operating Lease, Term of Contract	60 days

Note 7 - Leases - Future Minimu

Note 7 - Leases - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2019USD ($)
2020	$ 2,941
2021	2,742
2022	2,821
2023	2,904
2024	2,988
Thereafter	2,514
Total future minimum lease payments	16,910
Less: discount	(3,155)
Total lease liabilities	$ 13,755

Note 8 - Secured Notes to Rel_2

Note 8 - Secured Notes to Related Party (Details Textual) - USD ($)	Aug. 05, 2016	Aug. 02, 2016	Jul. 29, 2011	Aug. 31, 2018	Aug. 31, 2016	Apr. 30, 2011	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Convertible Debt Issuable in Connection with Private Placement						$ 4,500,000
Proceeds from Convertible Debt						$ 4,300,000
Amortization of Debt Discount (Premium)							$ 247,000	$ 210,000
Convertible Notes Payable, Related Parties, Current							4,821,000		$ 4,574,000
Interest Paid, Excluding Capitalized Interest, Operating Activities								500,000
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage						6.00%
Debt Instrument Conversion Ratio Multiple of Principal						$ 1,000
Beneficial Ownership after Conversion						9.99%
Notice Period Associated with Beneficial Ownership Percentage Limitation Convertible Notes						61 days
Common Shares Registered for Resale in Connection with Convertible Notes			3,500,000
Debt Instrument, Term						10 years
Paid-in-Kind Interest							100,000
Debt Instrument, Increase (Decrease), Other, Net							100,000
Interest Expense, Debt, Excluding Amortization							100,000	100,000
Amortization of Debt Discount (Premium)							200,000	200,000
Debt Instrument, Face Amount							6,900,000
Debt Instrument, Unamortized Discount, Total							$ 2,100,000
Debt Instrument, Convertible, Number Shares of Equity Insturments							8,600,000
Convertible Debt [Member] | Common Stock [Member]
Debt Instrument Conversion Ratio Shares						1,250
Term Loan [Member] | Tang Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Term					2 years
Debt Agreement, Maximum Borrowing Capacity					$ 100,000,000
Proceeds from Issuance of Long-term Debt, Total	$ 50,000,000
Proceeds from Issuance of Long-term Debt, Subject to Achievement of Corporate Milestone		$ 50,000,000
Debt Instrument, Fee Amount		$ 0
Debt Instrument, Number of Warrants		0
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 0
Interest Expense, Total								$ 500,000
Repayments of Long-term Debt, Total				$ 25,000,000
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 200,000
Long-term Debt, Total							$ 0

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Jun. 30, 2018	Apr. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Proceeds from Issuance of Common Stock	$ 194,400	$ 168,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net			732,000
Proceeds from Stock Options Exercised			$ 6,539	$ 4,202
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 100,300
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years 219 days
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	5,100,000	6,900,000
Share Price	$ 39.50	$ 26
Payments of Stock Issuance Costs	$ 5,600	$ 10,700

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Stock Option Activity (Details) - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of shares outstanding (in shares)	15,265
Number of shares outstanding, weighted average exercise price (in dollars per share)	$ 18.33
Number of shares outstanding, weighted average remaining contractual term (Year)	7 years 69 days	6 years 317 days
Number of shares granted (in shares)	253
Number of shares granted, weighted average exercise price (in dollars per share)	$ 25.99
Number of shares exercised (in shares)	(732)
Number of shares exercised, weighted average exercise price (in dollars per share)	$ 8.93
Expired and forfeited (in shares)	(505)
Number of shares expired and forfeited, weighted average exercise price (in dollars per share)	$ 21.11
Number of shares outstanding (in shares)	14,281	15,265
Number of shares outstanding, weighted average exercise price (in dollars per share)	$ 18.85	$ 18.33

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock-based compensation expense	$ 17,902	$ 7,701
Research and Development Expense [Member]
Stock-based compensation expense	5,324	3,036
General and Administrative Expense [Member]
Stock-based compensation expense	3,680	2,276
Selling and Marketing Expense [Member]
Stock-based compensation expense	$ 8,898	$ 2,389

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Valuation Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Risk-free interest rate	2.50%	2.60%
Dividend yield	0.00%	0.00%
Volatility	68.80%	71.40%
Expected life (Year)	6 years	6 years